NDA Sponsors Should Justify Dose Through Decision Analysis
Executive Summary
NDA sponsors should justify recommended doses for product labeling through a process of decision analysis, Clinical Pharmacology Subcommittee member Lewis Sheiner, MD, University of California-San Francisco, said